Loading clinical trials...
Loading clinical trials...
A Phase 1a/1b Open-label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Patients With Advanced or Metastatic Solid Tumors
Conditions
Interventions
TACH101
Locations
8
United States
UCI Health
Orange, California, United States
Sarah Cannon Research Institute
Denver, Colorado, United States
Sarah Cannon Research Institute
Orlando, Florida, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
NEXT Oncology
Austin, Texas, United States
MD Anderson
Houston, Texas, United States
Start Date
February 17, 2023
Primary Completion Date
July 1, 2025
Completion Date
July 1, 2025
Last Updated
August 1, 2024
NCT05720117
NCT06898450
NCT06658951
NCT05101070
NCT05098132
NCT05719558
Lead Sponsor
Tachyon Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions